From the NIH: “The National Institutes of Health is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing (which detects SARS-CoV-2 coronavirus). NIH’s Rapid Acceleration of Diagnostics (RADx) initiative has awarded contracts to seven biomedical diagnostic companies to support a range of new lab-based and point-of-care tests that could significantly increase […]
Big4Bio Q&A: Dror Bashan, CEO of Protalix BioTherapeutics
/ big4bio
LaVoieHealthScience Client Spotlight with Dror Bashan, CEO of Protalix BioTherapeutics Can you provide a brief overview of Protalix BioTherapeutics and its focus? Protalix BioTherapeutics is a unique biopharmaceutical company dedicated to bringing to market recombinant therapeutic proteins with clinically improved profiles, produced with our ProCellEx® plant cell-based expression. Protalix was the first company ever to gain FDA approval for […]